3-Bromo-5-trifluoromethylbenzenesulfonamide | 214210-15-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Bromo-5-trifluoromethylbenzenesulfonamide
• 英文别名: 3-bromo-5-(trifluoromethyl)benzenesulfonamide
• CAS: 214210-15-8
• 化学式: C₇H₅BrF₃NO₂S
• 分子量: 304.087
• InChiKey: BGCGGYKHNMWDKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  3-Bromo-5-trifluoromethylbenzenesulfonamide 、 C₁₀H₂₁NO 在 potassium phosphate 、 copper(l) iodide 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 生成 3-[(cis-5-hydroxy-1,3,3-trimethyl-cyclohexylmethyl)-amino]-5-trifluoromethyl-benzenesulfonamide
  参考文献：
  名称：

  Design and Synthesis of Benzenesulfonamide Derivatives as Potent Anti-Influenza Hemagglutinin Inhibitors

  摘要：

  Structural optimization of salicylamide-based hemagglutinin (HA) inhibitor 1 resulted in the identification of cis-3-(5-hydroxy-1,3,3-timethylcyclohexylmethylamino)benzenesulfonamide 28 and its derivatives as potent anti-influenza agents. The lead compound 28 and its 2-chloro analogue 40 can effectively prevent cytopathic effects (CPE) caused by infection of influenza A/Weiss/43 strain (H1N1) with EC(50) values of 210 and 86 nM, respectively. Mechanism of action studies indicate that 40 and its analogues inhibit the virus fusion with host endosome membrane by binding to HA and stabilizing the prefusion HA structure. With significantly improved metabolic stability, the reported series represents the first generation of orally bioavailable HA inhibitors that have a good selectivity window and potential for further development as novel anti-influenza agents.

  DOI：

  10.1021/ml2000627
• 作为产物：
  描述：

  3-氨基-5-溴三氟甲苯 在 盐酸 、 氨 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.17h， 生成 3-Bromo-5-trifluoromethylbenzenesulfonamide
  参考文献：
  名称：

  Design and Synthesis of Benzenesulfonamide Derivatives as Potent Anti-Influenza Hemagglutinin Inhibitors

  摘要：

  Structural optimization of salicylamide-based hemagglutinin (HA) inhibitor 1 resulted in the identification of cis-3-(5-hydroxy-1,3,3-timethylcyclohexylmethylamino)benzenesulfonamide 28 and its derivatives as potent anti-influenza agents. The lead compound 28 and its 2-chloro analogue 40 can effectively prevent cytopathic effects (CPE) caused by infection of influenza A/Weiss/43 strain (H1N1) with EC(50) values of 210 and 86 nM, respectively. Mechanism of action studies indicate that 40 and its analogues inhibit the virus fusion with host endosome membrane by binding to HA and stabilizing the prefusion HA structure. With significantly improved metabolic stability, the reported series represents the first generation of orally bioavailable HA inhibitors that have a good selectivity window and potential for further development as novel anti-influenza agents.

  DOI：

  10.1021/ml2000627

文献信息

• Phenethanolamine derivatives for treatment of respiratory diseases
  申请人：——

  公开号：US20040180876A1

  公开（公告）日：2004-09-16

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及一种新型化合物(I)、其制造方法、包含它们的药物组合物以及它们在治疗中的应用，特别是在呼吸系统疾病的预防和治疗中的应用。
• Pyridine derivatives and pharmaceutical compositions containing them
  申请人：AstraZeneca AB

  公开号：US06300352B1

  公开（公告）日：2001-10-09

  The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.

  该发明涉及新型吡啶衍生物，它们的用途作为药物，含有它们的制药配方和制备它们的方法。
• PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
  申请人：BIGGADIKE Keith

  公开号：US20060287286A1

  公开（公告）日：2006-12-21

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物、其制备方法、含有它们的制药组合物以及它们在治疗中的应用，特别是它们在预防和治疗呼吸系统疾病中的应用。
• Methods using phenethanolamine derivatives for treatment of respiratory diseases
  申请人：Biggadike Keith

  公开号：US20070004807A1

  公开（公告）日：2007-01-04

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物、其制造方法、含有它们的药物组合物，以及它们在治疗中的应用，特别是在呼吸系统疾病的预防和治疗中的应用。
• NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Astra Pharmaceuticals Limited

  公开号：EP0971892A1

  公开（公告）日：2000-01-19